Literature DB >> 2744011

Studies of variations of subcutaneously infused desferrioxamine and iron movements in thalassaemia children.

E A Llados i Vallory1, R Girot, G Lenoir, M Payet, P Houze, R Bourdon.   

Abstract

Desferrioxamine (DFO) plus ferrioxamine (FO) variations and alterations in plasma and urinary iron (Fe) levels were investigated in eight children with thalassaemia major during a 12-h s.c. DFO infusion at a dose of 40 mg/kg body weight. During the infusion, blood samples were regularly taken and total urine was also regularly collected in all patients. In the plasma, a mean DFO plus FO plateau level of 9 mg/l was reached after 4 h and remained steady in the subsequent 8 h. At 30 h the mean DFO plus FO concentration in plasma was still 4.5 mg/l. At 30 h, the urinary excretion ranged from 15% to 70% of the infused dose (mean: 42%). In plasma, the Fe concentration increased on average by 20% (range 10%-30%), remained steady during the DFO infusion, then returned to the basal level after 16-24 h. Urinary Fe excretion started early and still persisted 18 h after the infusion. The amount excreted at 30 h ranged from 5 to 27 mg (mean: 13.6 mg). This study emphasizes the delay in obtaining a DFO plus FO plateau in plasma, the important interindividual variations and the slow decrease of the drug after the end of the infusion. It points out the delay and the values of the urinary Fe excretion compared to the plasmatic and urinary drug variations.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2744011     DOI: 10.1007/bf00441542

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  20 in total

1.  Visual loss in patient on high-dose subcutaneous desferrioxamine.

Authors:  C Borgna-Pignatti; P De Stefano; A M Broglia
Journal:  Lancet       Date:  1984-03-24       Impact factor: 79.321

2.  Desferrioxamine, ocular toxicity, and trace metals.

Authors:  P Simon; K S Ang; A Meyrier; P Allain; Y Mauras
Journal:  Lancet       Date:  1983-08-27       Impact factor: 79.321

3.  Haemoglobin levels and blood requirement in thalassaemia.

Authors:  V Gabutti; A Piga; P Nicola; C Vullo; L Capra; A Di Palma; G Masera; S Terzoli; R Mauri
Journal:  Arch Dis Child       Date:  1982-02       Impact factor: 3.791

4.  Ferrioxamine excretion in iron-loaded man.

Authors:  M J Pippard; S T Callender; C A Finch
Journal:  Blood       Date:  1982-08       Impact factor: 22.113

5.  Clinical management of thalassemia. Decreasing iron stores during intensive chelation therapy.

Authors:  A Cohen; E Schwartz
Journal:  Ann N Y Acad Sci       Date:  1980       Impact factor: 5.691

6.  Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects.

Authors:  M R Summers; A Jacobs; D Tudway; P Perera; C Ricketts
Journal:  Br J Haematol       Date:  1979-08       Impact factor: 6.998

7.  Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients.

Authors:  S De Virgiliis; P Cossu; C Toccafondi; G Sanna; F Frau; R Lobrano; G Cornacchia; A Nucaro; A Loi; F Bertolino; A Cao
Journal:  Am J Pediatr Hematol Oncol       Date:  1983

8.  [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].

Authors:  N Krüger; H Kijewski; R König; W Tillmann; W Schröter
Journal:  Dtsch Med Wochenschr       Date:  1984-11-02       Impact factor: 0.628

9.  Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload.

Authors:  G E Janka; P Möhring; M Helmig; R J Haas; K Betke
Journal:  Eur J Pediatr       Date:  1981-11       Impact factor: 3.183

10.  Prevention of iron loading in transfusion-dependent thalassaemia.

Authors:  M J Pippard; E A Letsky; S T Callender; D J Weatherall
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

View more
  3 in total

1.  Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine.

Authors:  V De Sanctis; A Pinamonti; A Di Palma; M Sprocati; G Atti; M R Gamberini; C Vullo
Journal:  Eur J Pediatr       Date:  1996-05       Impact factor: 3.183

2.  Specific iron chelators determine the route of ferritin degradation.

Authors:  Ivana De Domenico; Diane McVey Ward; Jerry Kaplan
Journal:  Blood       Date:  2009-08-11       Impact factor: 22.113

3.  Drug-induced reactivation of apoptosis abrogates HIV-1 infection.

Authors:  Hartmut M Hanauske-Abel; Deepti Saxena; Paul E Palumbo; Axel-Rainer Hanauske; Augusto D Luchessi; Tavane D Cambiaghi; Mainul Hoque; Michael Spino; Darlene D'Alliessi Gandolfi; Debra S Heller; Sukhwinder Singh; Myung Hee Park; Bernadette M Cracchiolo; Fernando Tricta; John Connelly; Anthony M Popowicz; Richard A Cone; Bart Holland; Tsafi Pe'ery; Michael B Mathews
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.